火星文

Chinese researchers identify target to develop depression drug using traditional ethnic medicine in Yunnan_我的网站

A |     

    Qingyangshen, or Root of Auricledleaf Swallowwort, a traditional ethnic medicinal plant long used in Southwest China's Yunnan Province. Photo: Scrrenshot from website
A Chinese research team has identified a new potential target to develop antidepressant drug from Qingyangshen, or Root of Auricledleaf Swallowwort, a traditional ethnic medicinal plant long used in Southwest China's Yunnan Province, according to Kunming University of Science and Technology, Science and Technology Daily reported Sunday.
The team, led by professors Xu Tianrui and Xiang Cheng from the university's School of Life Science and Technology, found that Qingyangshen glycosides, the plant's core active compound, can alleviate depression-related behaviors by simultaneously suppressing inflammation, reducing oxidative damage and stabilizing neurotransmitters in the brain.
The findings were published in the international journal Phytomedicine.  
Depression has become a widespread mental health disorder globally, while existing clinical drugs fail to provide effective treatment for more than 30 percent of patients, according to the researchers. Previous studies have established a strong link between chronic inflammation and depression, but existing anti-inflammatory drugs have limited targeting capabilities, underscoring the need for new therapeutic targets and lead compounds.
Qingyangshen, a plant of the Cynanchum genus in the Apocynaceae family, has long been used as a traditional medicine by ethnic groups including the Naxi, Yi and Bai peoples in Yunnan, mainly for treating neurological conditions such as epilepsy and neurasthenia. 
The researchers systematically examined the pharmacological effects of Qingyangshen extract and its core active compound, Qingyangshen glycosides. Tests using mouse, zebrafish and fruit fly models repeatedly showed that the compound significantly improved depression-related behaviors induced by inflammation, according to the report.
To identify the compound's target, the team developed a dual-discrimination model for four subtypes of prostaglandin E2 receptors and combined it with AI-powered machine learning. The researchers screened hundreds of G protein-coupled receptors and identified the prostaglandin E2 subtype 4 receptor as the direct target of Qingyangshen glycosides.
Multiple molecular experiments confirmed that the compound binds directly to the receptor and acts as an inhibitory ligand. Further experiments involving animals with the receptor knocked out in the hippocampus showed that the antidepressant effects of Qingyangshen glycosides disappeared completely when the receptor was absent, providing the first in-vivo evidence that the receptor is essential for the compound's therapeutic effects.
    An illustration of the research. Photo: Screenshot from the website
The study establishes the prostaglandin E2 subtype 4 receptor as a potential new target for antidepressant drug development and points to a new approach to treating depression through inflammatory pathways. It also identifies Qingyangshen glycosides as a potential lead compound for developing highly targeted anti-inflammatory antidepressants, creating a research chain from ethnic medicinal plants and active compounds to drug targets and new drug development.
Global Times
。    　　欧菲光：上半年亏损4.44亿元     人民财讯8月25日电，欧菲光(002456)8月25日披露半年报，2026年上半年，公司实现营业收入78.41亿元，同比下降20.29%；归属于上市公司股东的净利润为-4.44亿元，上年同期亏损1.09亿元。报告期内，受存储芯片大幅涨价，下游终端市场需求走弱，部分终端厂商主动下调生产及出货计划，公司销售订单规模阶段性减少，导致公司主营业务毛利减少；公司获取的与收益相关的政府补助同比减少。    。

Current article:http://sm25.diapoqiechuangpenghua.sbs/n27p/20260826/4190.html

Published on:02:35:40